Melioidosis

Overview
Melioidosis is an infectious disease caused by the Gram‑negative bacterium Burkholderia pseudomallei. The organism is found in soil and surface water in tropical and subtropical regions, particularly in Southeast Asia and northern Australia. Human infection occurs primarily through percutaneous inoculation, inhalation, or ingestion of contaminated material.

Epidemiology

• Geographic distribution: Endemic in Thailand, Vietnam, Malaysia, Singapore, Indonesia, the Philippines, and the northern territories of Australia (especially the “Top End” of the Northern Territory). Sporadic cases have been reported in other tropical regions and among travelers returning from endemic areas.
• Incidence: In Thailand, reported incidence ranges from 1 to 20 cases per 100,000 population annually; in northern Australia, incidence can exceed 20 per 100,000 during the rainy season.
• Risk factors: Diabetes mellitus, chronic kidney disease, alcoholism, chronic lung disease, and immunosuppression increase susceptibility. Occupational exposure (e.g., rice farming, construction) and exposure during the rainy season are also associated with higher risk.

Pathogenesis and Transmission
B. pseudomallei can survive in diverse environmental conditions and is capable of intracellular replication within macrophages and other host cells. Transmission routes include:

• Percutaneous: Skin abrasions or wounds contaminated with moist soil or water.
• Inhalation: Aerosolized bacteria during heavy rains, storms, or dust storms.
• Ingestion: Contaminated water or food.
  Human‑to‑human transmission is rare but has been documented in neonatal and laboratory settings.

Clinical Presentation
Melioidosis is termed “the great mimicker” because it can manifest in multiple forms:

• Acute septicemic melioidosis: Fever, chills, hypotension, multi‑organ failure; high mortality if untreated.
• Localized disease: Skin or soft‑tissue abscesses, osteomyelitis, septic arthritis.
• Pulmonary melioidosis: Pneumonia with cough, chest pain, infiltrates on imaging; may progress to respiratory failure.
• Chronic melioidosis: Similar to tuberculosis with prolonged symptoms, weight loss, and pulmonary lesions.
• Latent infection: Asymptomatic individuals may develop disease months to years after exposure.

Diagnosis

• Microbiological culture: Isolation of B. pseudomallei from blood, sputum, urine, pus, or tissue is the gold standard. The organism exhibits characteristic oxidase positivity, resistance to many β‑lactams, and a distinctive “safety‑pin” appearance on Gram stain.
• Molecular methods: PCR assays targeting species‑specific genes (e.g., TTSS1, type III secretion system) provide rapid detection, especially when cultures are negative.
• Serology: Indirect hemagglutination assay (IHA) can indicate exposure but has limited specificity and is not reliable for acute diagnosis.
• Imaging: Chest radiography or CT may reveal consolidations, cavitations, or nodules; ultrasound and MRI assist in locating deep abscesses.

Treatment
Melioidosis requires a two‑phase antimicrobial regimen:

1. Intensive phase (10‑14 days, may be extended):

   • Intravenous ceftazidime (2 g every 6–8 h) or meropenem (1 g every 8 h) for severe disease.
   • Alternative: Imipenem or a combination of amoxicillin–clavulanic acid in less severe cases.

2. Eradication (consolidation) phase (3‑6 months):

   • Oral trimethoprim‑sulfamethoxazole (TMP‑SMX) is the standard.
   • Alternatives include doxycycline plus TMP‑SMX or amoxicillin‑clavulanic acid for patients intolerant to TMP‑SMX.

Therapeutic monitoring includes repeat cultures to confirm bacteriological clearance and regular assessment for drug toxicity.

Prevention

• Environmental measures: Use of protective footwear and gloves during soil or water exposure; avoidance of contaminated water for drinking or recreational purposes in endemic areas.
• Public health actions: Education of at‑risk populations, especially diabetics, about safe practices during the rainy season.
• Vaccination: No licensed vaccine exists; research into candidate vaccines is ongoing but remains experimental.

Prognosis
Mortality rates vary by disease severity and access to appropriate therapy. Acute septicemic melioidosis can have mortality >40 % without treatment, decreasing to <10 % with timely appropriate antibiotics. Chronic disease carries a better prognosis but may relapse if eradication therapy is incomplete.

History
The disease was first described in 1912 in Rangoon (now Yangon, Myanmar) by Captain Alfred Whitmore and C.S. Krishnaswami, who named it “glanders of the Malay Peninsula.” The term “melioidosis” (from Greek “melis,” meaning “honey” and “-oidēs,” meaning “resembling”) was introduced in the 1930s to reflect the disease’s similarity to glanders caused by Burkholderia mallei.

Research Directions
Current investigations focus on:

• Development of rapid point‑of‑care diagnostics.
• Identification of virulence factors to inform therapeutic targets.
• Evaluation of novel antimicrobial agents and combination regimens.
• Exploration of vaccine candidates, including live‑attenuated and subunit formulations.

References (selected)

1. Currie BJ, et al. Melioidosis: Epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2010.
2. Limmathurotsakul D, et al. Global burden of melioidosis. Nat Rev Microbiol. 2016.
3. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Infection. 2005.

This entry reflects current knowledge as of 2026 and is based on peer‑reviewed scientific literature and reputable public health sources.